Induced hepatocytes and uses thereof
AssigneeAccelerated Biosciences Corp.
InventorsJau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee, Eing-Mei Tsai
Life of this patent
Estimating the term…
Abstract
Disclosed herein are induced hepatocytes from a trophoblast stem cell, methods for inducing the cells, and compositions thereof. Also disclosed herein are methods of treating a disease or disorder (e.g., liver-associated) by utilizing an induced hepatocyte disclosed herein.
Claims17
An isolated human hepatocyte, wherein the isolated human hepatocyte endogenously expresses human leukocyte antigen G (HLA-G) and is a human hepatic progenitor cell, and wherein the isolated human hepatocyte further expresses one or more biomarkers from C-X-C chemokine receptor type 4 (CXCR4), forkhead box protein A2 (FOXA2), hematopoietically expressed homeobox (HHEX), cytochrome P450 7A1 (CYP7A1), bile salt export pump (BSEP), alpha-1-antitrypsin member 1 (SERPINA1), ATP-binding cassette sub-family C member 2 (ABCC2), CCAAT-enhancer-binding protein beta (C/EBPβ), hepatocyte nuclear factor 1-alpha (HNF1α), or any combination thereof.
A method of screening a therapeutic compound for use in treatment or prevention of a condition, comprising:
- a) contacting an isolated human hepatocyte with the therapeutic compound;
- and
- b) detecting an expression level of a biomarker in the isolated human hepatocyte,
- wherein the isolated human hepatocyte endogenously expresses human leukocyte antigen G (HLA-G) and is a human hepatic progenitor cell, and wherein the isolated human hepatocyte further expresses one or more biomarkers from C—X—C chemokine receptor type 4 (CXCR4), forkhead box protein A2 (FOXA2), hematopoietically expressed homeobox (HHEX), cytochrome P450 7A1 (CYP7A1), bile salt export pump (BSEP), alpha-1-antitrypsin member 1 (SERPINA1), ATP-binding cassette sub-family C member 2 (ABCC2), CCAAT-enhancer-binding protein beta (C/EBPβ), hepatocyte nuclear factor 1-alpha (HNF1α), or any combination thereof.
A method of treating a disorder of liver tissue or liver function in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises an isolated human hepatocyte in an amount effective for the isolated human hepatocytes to engraft to the subject, wherein the isolated human hepatocyte endogenously expresses human leukocyte antigen G (HLA-G) and is a human hepatic progenitor cell, and wherein the isolated human hepatocyte further expresses one or more biomarkers from C—X—C chemokine receptor type 4 (CXCR4), forkhead box protein A2 (FOXA2), hematopoietically expressed homeobox (HHEX), cytochrome P450 7A1 (CYP7A1), bile salt export pump (BSEP), alpha-1-antitrypsin member 1 (SERPINA1), ATP-binding cassette sub-family C member 2 (ABCC2), CCAAT-enhancer-binding protein beta (C/EBPβ), hepatocyte nuclear factor 1-alpha (HNF1α), or any combination thereof, whereby the disorder is treated.
Dependencies are inferred from the claim text.